Should I Buy FHTX? FHTX 2026 Analysis

Should You Buy Foghorn Therapeutics Inc (FHTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

5.680

1 Day change

8.60%

52 Week Range

6.950

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient investor: near-term technicals are weakening and options flow is bearish (put-heavy volume spike).
Long-term story remains attractive (multiple Wall St. Buy initiations and 2026 clinical readouts), but the current tape favors more downside/chop before a cleaner entry.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/velocity: MACD histogram is negative (-0.077) and expanding lower, signaling bearish momentum is building rather than stabilizing.
RSI: RSI(6) at 39.29 is weak (near oversold territory but not flashing a reversal), consistent with continued selling pressure.
Moving averages: converging MAs suggest compression/indecision, but with MACD negative this leans to a bearish breakdown risk rather than an upside breakout.
Key levels: price (5.61 post-market) is below the pivot (5.849).
- Support: S1 5.522 then S2 5.32 (a break below 5.52 increases odds of acceleration down).
- Resistance: R1 6.175 then R2 6.377 (needs a reclaim to shift momentum).
Pattern-based forward bias: similar-pattern stats imply modest upside next day (+0.97%) but negative drift over 1 week (-1.21%) and 1 month (-2.47%).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning (OI): Put/Call OI ratio 0.77 = more calls than puts in open interest (mildly bullish positioning).
Flow (volume): Put/Call volume ratio 0.0 with call volume 0 and put volume 200 indicates today’s activity was put-dominant (bearish/hedging), despite bullish-leaning OI.
Volume shock: today’s option volume is ~2222% of the 30-day average, flagging unusual sentiment/positioning activity.
Volatility: 30D IV ~220.94% (very high in absolute terms), but IV rank ~17 and IV percentile ~30 suggest IV is not elevated versus its own recent history; also IV is trending down vs 5D/10D averages (cooling after prior spike).

Technical Summary

Sell

Buy

Positive Catalysts

- Wall Street setup into 2026 Phase 1 data: multiple firms initiated with Buy ratings and $11–$12 targets, explicitly citing undervaluation into upcoming clinical readouts.
- Partnered lead asset: FHD-909 is partnered 50/50 with Eli Lilly; partnership can de-risk development and strengthen funding/credibility.
- Runway: sell-side commentary indicates cash runway into 2028, reducing near-term financing overhang.

Neutral/Negative Catalysts

- No news/catalysts in the past week; without a near-term event, the stock is more likely to follow technical/flow-driven drift.
- Bearish near-term momentum: negative and worsening MACD plus weak RSI increases probability of a support retest (5.52/5.32).
- Options tape warning: unusually large put volume with zero call volume suggests near-term cautious/bearish sentiment.
- Biotech execution risk remains high into 2026 readouts (binary clinical outcomes).

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $8.153M, +4.42% YoY (modest growth).
Profitability: net loss widened to -$15.849M (down -17.12% YoY), indicating higher burn.
EPS: -$0.25, worse by -19.35% YoY.
Gross margin: 100% (typical for collaboration/other revenue mix), but overall losses are still expanding—growth is not yet translating into improving earnings.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: coverage was initiated by Guggenheim (Buy, $12) on 2025-11-07, Stifel (Buy, $12) on 2025-12-03, and BTIG (Buy, $11) on 2025-12-18—consistently bullish initiations with high implied upside vs the current ~$5.6 price.
Wall Street pros: undervaluation thesis, clear upcoming clinical milestones (initial Phase 1 data in 2026), and Lilly partnership plus runway narrative.
Wall Street cons: value is largely milestone-driven and delayed (data in 2026; commercialization modeled much later), so the stock can drift lower/sideways when technicals sour and catalysts are not imminent.
Other flows: hedge funds neutral; insiders neutral; no recent Congress trading data; no politician/influential figure activity provided.

9 Analyst Rating

Wall Street analysts forecast FHTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FHTX is 11.38 USD with a low forecast of 9 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.230

Low

Averages

11.38

High

Current: 5.230

Low

Averages

11.38

High

BTIG

Buy

initiated

$11

AI Analysis

2025-12-18

Reason

BTIG

Price Target

$11

AI Analysis

2025-12-18

initiated

Buy

Reason

BTIG initiated coverage of Foghorn Therapeutics with a Buy rating and $11 price target. The firm says Foghorn is a clinical-stage biopharmaceutical company developing novel inhibitors and degraders for various oncology indications. BTIG views the shares undervalued into the company's Phase 1 data in 2026. The share setup is favorable into the readout for FHD-909, a "potent and selective" inhibitor of SMARCA2 currently in Phase 1a dose escalation for solid tumors, BTIG contends.

Stifel

initiated

$12

2025-12-03

Reason

Stifel

Price Target

$12

2025-12-03

initiated

Reason

Stifel initiated coverage of Foghorn Therapeutics (FHTX) with a Buy rating and $12 price target. Lead asset FHD-909, partnered 50/50 with Eli Lilly (LLY), expects initial data in 2026, notes the analyst, who models a 2030 launch and about $1.4B in global peak sales, including about $500M to Foghorn. The company's cash runway extends into 2028, well past initial FHD-909 proof-of-concept data and likely the first degrader data set, the analyst tells investors.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FHTX

Unlock Now

FHTX Should I Buy

FHTX Should I Buy

Should You Buy Foghorn Therapeutics Inc (FHTX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch